VISION2030: A Forecast for the Field

VISION2030 gathers business-founding scientists and CEOs for in-depth interviews on a decade past and decade ahead. Where we are now, obstacles to overcome, and what is next: for our field, businesses, careers. This gathering comes at a pivotal moment in regenerative medicine and stem cell science, as discovery, translation, and investment intersect. This digital meeting will take place 7-8 January, 2021.

View On-Demand

Program Organizers

Hans C. Clevers
ISSCR Past President, Hubrecht Institute, Netherlands

Deepak Srivastava
ISSCR Immediate Past President, Gladstone Institutes/UCSF, USA

Douglas A. Melton
ISSCR Past President, Harvard University, USA

Leonard I. Zon
ISSCR Founder, Boston Children’s Hospital, USA, ISSCR Founder

Christine L. Mummery
ISSCR President, Leiden University Medical Center, Netherlands

Program (view full program)

Thursday, 7 January (12:00 - 17:30 EST)

Welcome Remarks

Christine Mummery, ISSCR President, Leiden University Medical Center, Netherlands
Deepak Srivastava, ISSCR Immediate Past President, Gladstone Institute/UCSF, USA
Leonard I. Zon, ISSCR Founder, Boston Children’s Hospital, USA

BlueRock Therapeutics Executive Interview

Emile Nuwaysir, President and Chief Executive Officer, BlueRock Therapeutics, USA

Lorenz Studer, Founding Scientist, BlueRock Therapeutics l Sloan Kettering Institute for Cancer Research, USA

Viviane Tabar, Founding Scientist, BlueRock Therapeutics l Memorial Sloan Kettering Center, USA

Interviewed by ISSCR Board Member Arnold Kriegstein, University of California, San Francisco, USA

BlueRock Therapeutics is advancing their novel cell+gene platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies across three therapeutic areas: neurology, cardiology, and immunology.

Surrozen Executive Interview

Craig Parker, Chief Executive Officer, Surrozen, USA

Claudia Janda, Princes Máxima Centrum, Netherlands l Surrozen Founder

Interviewed by ISSCR Past President Hans C. Clevers, Hubrecht Institute, Netherlands l Surrozen

Surrozen is pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues and restore organs damaged by serious disease.

ElevateBio Executive Interview

Mitchell Finer, Scientific Founder and President, ElevateBio, USA

Melissa Carpenter, Chief Scientific Officer, ElevateBio, USA

Interviewed by ISSCR Board Member Martin Pera, The Jackson Laboratories, USA l Stem Cell Reports Editor-in-Chief

ElevateBio is accelerating the rate of innovation in cell and gene therapy with a disruptive capital-efficient model.

STEMCELL Technologies Executive Interview

Allen Eaves, Scientific Founder l Chief Executive Officer, STEMCELL Technologies, Canada

Interviewed by ISSCR Board Member Valentina Greco, Yale University School of Medicine, USA

STEMCELL Technologies' mission is to advance the pursuit of scientific knowledge by supplying high quality, innovative reagents, tools and services that enable life science research.

Vertex Pharmaceuticals Executive Interview

Jeffrey Leiden, Executive Chairman, Vertex Pharmaceutical, USA

Bastiano Sanna, Executive Vice President, Chief of Cell & Genetic Therapies & VCGT Site Head, Vertex Pharmaceuticals, USA

Interviewed by ISSCR Past President Douglas A. Melton, Scientific Founder, Semma Therapeutics, now Vertex Pharmaceutical l Harvard University, USA

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.

Futurecast—STEMCELL Technologies

(Sponsored Content)

Andrew Gaffney, Associate Director, iPSC and Differentiated Cells

Tenaya Therapeutics Executive Interview

Faraz Ali, Chief Executive Officer, Tenaya Therapeutics, USA

Deepak Srivastava, Scientific Founder, Tenaya Therapeutics l Gladstone Institute/UCSF, USA l ISSCR Immediate Past President

Interviewed by ISSCR Board Member Charles E. Murry, Institute for Stem Cell and Regenerative Medicine, University of Washington/Sana Biotechnologies, USA

Tenaya Therapeutics is a company with a mission to discover, develop, and deliver curative therapies that target the underlying causes of heart disease.

Fate Therapeutics Executive Interview

Scott Wolchko, President and Chief Executive Officer, Fate Therapeutics, USA

Leonard I. Zon, Scientific Founder, Fate Therapeutics l Boston Children’s Hospital, USA l ISSCR Founder

Interviewed by ISSCR Board Member Takanori Takebe, Cincinnati Children's Hospital Medical Center, USA/Tokyo Medical and Dental University and Yokohama City University, Japan 

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders. 

Thought Leaders—Pivoting to the Future

Panelists interviewed by Deepak Srivastava
ISSCR Immediate Past President/President, Gladstone Institutes, USA

Margaret A. Hamburg, Co-Chair, WHO Expert Advisory Group On Developing Global Standards for Governance and Oversight of Human Genome Editing and Global Standards for Governance and Oversight of Human Genome Editing l Former FDA Commissioner, USA

Rajiv Kaul, Sector Manager, Fidelity Select Biotechnology Portfolio and Fidelity Advisor Biotechnology Fund, USA

Andrew Plump, President, Research & Development, Takeda Pharmaceutical Company Limited and Member of the Board of Directors, USA

Jim Tananbaum, Founder and Chief Executive Officer, Foresite Capital, USA

Concluding Remarks

Christine Mummery, ISSCR President, Leiden University Medical Center, Netherlands

Friday, 8 January (12:00 - 13:30 EST)

Sponsored Industry Career Talks

Join us as participating companies discuss how the future of our field will shape the future of our careers – new opportunities, paths, and challenges. Attendees will hear from HR Leaders and scientists, discussing the transition from academia to industry, how to make it, and what to expect.  

Welcome

Keith Alm, Chief Operating Officer, International Society for Stem Cell Research (ISSCR), USA

Julia Tischler, ISSCR Membership Committee l Research Scientist in Stem Cell Biology and Bioengineering, École Polytechnique Fédérale de Lausanne, Switzerland